The government’s decision to grant a compulsory licence for the manufacture of an important anti-cancer drug should be the first step towards making available essential drugs at little or no direct cost.
Read more: The Hindu, March 14, 2012
-
Recent Posts
- The EU says no to ACTA: to protect public health, other countries should also reject it
- Compulsory Licensing in India: A historic move to make drugs affordable
- Open letter to DG, WHO – Pentavalent vaccine related deaths in India
- Global Week of Action: India- EU Free Trade Agreement (FTA)
- A victory for Novartis could spell death for millions
Tags
ACTA AIDAN Annual Meet Book release Clinical Trials Conflict of Interest draft policy Drug Pricing Drug Promotion Essential Drugs essential medicines EU Generic drug Global Health Health India India-EU FTA IPR Letter Marketing Medical Council of India Medicine Medicine pricing Medicines National Pharmaceuticals Pricing Policy Patent Pharma Industry Pharma Policy Photo PIL Polio Price Control Rational Drugs Sec 3 (d) Supreme Court of India TRIPS Vaccine WHO WTOBlog Stats
- 42,000 hits
